{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:32:06Z","timestamp":1793493126458,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Berger-Janser Foundation"},{"name":"RECETOX Research Infrastructure","award":["LM2015051 and CZ.02.1.01\/0.0\/0.0\/16_013\/0001761"],"award-info":[{"award-number":["LM2015051 and CZ.02.1.01\/0.0\/0.0\/16_013\/0001761"]}]},{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zonta Group Bern"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5752-8","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T12:02:43Z","timestamp":1559908963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases"],"prefix":"10.1186","volume":"19","author":[{"given":"Mariana","family":"Bustamante Eduardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Imboden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Ballabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00f6rg","family":"Altermatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"G\u00fcnthert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5975-9607","authenticated-orcid":false,"given":"Rolf","family":"Jaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"issue":"9472","key":"5752_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet"},{"issue":"2","key":"5752_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4048\/jbc.2015.18.2.160","volume":"18","author":"S Park","year":"2015","unstructured":"Park S, Han W, Kim J, Kim MK, Lee E, Yoo T-K, Lee H-B, Kang YJ, Kim Y-G, Moon H-G, et al. Risk factors associated with distant metastasis and survival outcomes in breast Cancer patients with Locoregional recurrence. J Breast Cancer. 2015;18(2):160\u20136.","journal-title":"J Breast Cancer"},{"issue":"3","key":"5752_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1524-4741.2009.00716.x","volume":"15","author":"B Sirohi","year":"2009","unstructured":"Sirohi B, Leary A, Johnston SRD. Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy? Breast J. 2009;15(3):268\u201378.","journal-title":"Breast J"},{"issue":"6797","key":"5752_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"C Perou","year":"2000","unstructured":"Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"19","key":"5752_CR5","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869\u201374.","journal-title":"Proc Natl Acad Sci"},{"issue":"21","key":"5752_CR6","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"JS Parker","year":"2010","unstructured":"Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin Cancer Res. 2010;16(21):5222\u201332.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5752_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5752_CR8","first-page":"54","volume":"8","author":"B Wallden","year":"2015","unstructured":"Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genet. 2015;8(1):54.","journal-title":"BMC Med Genet"},{"issue":"11","key":"5752_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast Cancer treated with Anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829\u201334.","journal-title":"J Clin Oncol"},{"issue":"27","key":"5752_CR10","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast Cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"21","key":"5752_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005\u201314.","journal-title":"N Engl J Med"},{"issue":"18","key":"5752_CR12","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","volume":"17","author":"M Filipits","year":"2011","unstructured":"Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5752_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2014.09.014","volume":"355","author":"F Bertucci","year":"2014","unstructured":"Bertucci F, Finetti P, Viens P, Birnbaum D. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett. 2014;355(1):70\u20135.","journal-title":"Cancer Lett"},{"issue":"1","key":"5752_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2407-10-37","volume":"10","author":"J Antonov","year":"2010","unstructured":"Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Th\u00fcrlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, et al. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010;10(1):37.","journal-title":"BMC Cancer"},{"issue":"31","key":"5752_CR15","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5752_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"M Cheang","year":"2009","unstructured":"Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard P, Parker J. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"5752_CR17","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/annonc\/mds586","volume":"23","author":"S Guiu","year":"2012","unstructured":"Guiu S, Michiels S, Andr\u00e9 F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Ann Oncol. 2012;23(12):2997\u20133006.","journal-title":"Ann Oncol"},{"issue":"7","key":"5752_CR18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DMA Gendoo","year":"2016","unstructured":"Gendoo DMA, Ratanasirigulchai N, Schr\u00f6der MS, Par\u00e9 L, Parker JS, Prat A, Haibe-Kains B. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32(7):1097\u20139.","journal-title":"Bioinformatics"},{"issue":"1","key":"5752_CR19","first-page":"9","volume":"1","author":"A Oberli","year":"2008","unstructured":"Oberli A, Popovici V, Delorenzi M, Baltzer A, Antonov J, Matthey S, Aebi S, Altermatt H, Jaggi R. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genet. 2008;1(1):9.","journal-title":"BMC Med Genet"},{"issue":"1","key":"5752_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/1471-2407-8-343","volume":"8","author":"M Schobesberger","year":"2008","unstructured":"Schobesberger M, Baltzer A, Oberli A, Kappeler A, Gugger M, Burger H, Jaggi R. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMC Cancer. 2008;8(1):343.","journal-title":"BMC Cancer"},{"issue":"3","key":"5752_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt1385","volume":"26","author":"G Geiss","year":"2008","unstructured":"Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D, Fell H, Ferree S, George R, Grogan T. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317\u201325.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"5752_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/bioinformatics\/bts188","volume":"28","author":"D Waggott","year":"2012","unstructured":"Waggott D, Chu K, Yin S, Wouters BG, Liu F-F, Boutros PC. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012;28(11):1546\u20138.","journal-title":"Bioinformatics"},{"issue":"25","key":"5752_CR23","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","volume":"95","author":"MB Eisen","year":"1998","unstructured":"Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95(25):14863\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"5752_CR24","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1073\/pnas.0506230102","volume":"102","author":"LD Miller","year":"2005","unstructured":"Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5752_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jnci\/djj052","volume":"98","author":"C Sotiriou","year":"2006","unstructured":"Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast Cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262\u201372.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"5752_CR26","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-12-0286","volume":"18","author":"SK Chia","year":"2012","unstructured":"Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465\u201372.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5752_CR27","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast Cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684\u201391.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5752_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4048\/jbc.2016.19.2.176","volume":"19","author":"G Wen","year":"2016","unstructured":"Wen G, Zhang J-S, Zhang Y-J, Zhu Y-J, Huang X-B, Guan X-X. Predictive value of molecular subtyping for Locoregional recurrence in early-stage breast Cancer with N1 without Postmastectomy radiotherapy. J Breast Cancer. 2016;19(2):176\u201384.","journal-title":"J Breast Cancer"},{"issue":"5","key":"5752_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaoncol.2016.5630","volume":"3","author":"N Priedigkeit","year":"2017","unstructured":"Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic subtype switching and acquired erbb2\/her2 amplifications and mutations in breast cancer brain metastases. JAMA Oncology. 2017;3(5):666\u201371.","journal-title":"JAMA Oncology"},{"key":"5752_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.semcancer.2015.08.009","volume":"35","author":"S Kimbung","year":"2015","unstructured":"Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015;35:85\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"5752_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3892\/ol.2017.6166","volume":"14","author":"NE Oehrlich","year":"2017","unstructured":"Oehrlich NE, Spineli LM, Papendorf F, Park-Simon T-W. Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncol Lett. 2017;14(1):194\u2013200.","journal-title":"Oncol Lett"},{"issue":"4","key":"5752_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw259","volume":"109","author":"EP Mamounas","year":"2017","unstructured":"Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong J-H, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, et al. 21-gene recurrence score and Locoregional recurrence in node-positive\/ER-positive breast Cancer treated with chemo-endocrine therapy. JNCI. J Natl Cancer Inst. 2017;109(4):1\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"5752_CR33","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","volume":"28","author":"EP Mamounas","year":"2010","unstructured":"Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D Jr. CEG, Wickerham DL, Wolmark N: association between the 21-gene recurrence score assay and risk of Locoregional recurrence in node-negative, estrogen receptor\u2013positive breast Cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677\u201383.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5752_CR34","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/bjc.2015.98","volume":"112","author":"F Fitzal","year":"2015","unstructured":"Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer. 2015;112(8):1405\u201310.","journal-title":"Br J Cancer"},{"issue":"6","key":"5752_CR35","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/1078-0432.CCR-11-1954","volume":"18","author":"N Servant","year":"2012","unstructured":"Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hup\u00e9 P, Hadhri R, et al. Search for a gene expression signature of breast Cancer local recurrence in young women. Clin Cancer Res. 2012;18(6):1704\u201315.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5752_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058483","volume":"8","author":"Z Varga","year":"2013","unstructured":"Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, Tausch C, Trojan A, Moch H. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast Cancer. PLoS One. 2013;8(3):e58483.","journal-title":"PLoS One"},{"issue":"12","key":"5752_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s12325-015-0269-2","volume":"32","author":"MD Alvarado","year":"2015","unstructured":"Alvarado MD, Prasad C, Rothney M, Cherbavaz DB, Sing AP, Baehner FL, Svedman C, Markopoulos CJ. A prospective comparison of the 21-gene recurrence score and the PAM50-based Prosigna in estrogen receptor-positive early-stage breast Cancer. Adv Ther. 2015;32(12):1237\u201347.","journal-title":"Adv Ther"},{"issue":"51","key":"5752_CR38","first-page":"S324","volume":"2015","author":"R Jaggi","year":"1971","unstructured":"Jaggi R, Varga Z, Bigler M, Bize V, Bustamante Eduardo M, Berardi S, Chiesa F, Dedes KJ, M\u00fcller A, Tausch C, et al. A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26\/10). Eur J Cancer. 1971;2015(51):S324.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5752-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:12:21Z","timestamp":1591398741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5752-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5752"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5752-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clinical studies have to be presented to Cantonal Ethics Committees in Switzerland. Material that was used for this study was from patients and pathological samples that were collected in part before 1990 when informed consents were not commonly used. The Swiss law allows the use of such material under specific and very restrictive conditions. The Cantonal Ethics Committee of the Canton Bern examined the study and approved it on January, 18, 2018. The reference number is Ref 2017\u201302025.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"549"}}